Study design and patient characteristics
- An open-label, re-dosing extension study in patients who previously participated in clinical studies of SPINRAZA® (ENDEAR, CHERISH, EMBRACE, CS12* or CS3a)1
- Patients are diagnosed with infantile-onset (Type I) or later-onset (Type II/III) SMA1
- All patients in SHINE are receiving SPINRAZA® 12-mg1
- The study is ongoing
*Study CS12 involved re-dosing patients who had previously participated in studies CS1, CS2 and CS10.
Bill
age 48*Later-onset (Type III) SMA
treated with SPINRAZA®
*Age at time of photo shoot.
References:
1. SPINRAZA® Summary of Product Characteristics.